



PATENT
Attorney Docket No.: A-63096/RFT/JJD
(Genentech Ref. P993)

AF
160
#30/E
02/27/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bruce A. KEYT, et al.

Serial No.: 08/734,443

Filed: October 17, 1996

For: VARIANTS OF VASCULAR
ENDOTHELIAL GROWTH
FACTOR HAVING
ANTAGONISTIC PROPERTIES

) Examiner: SAOUD, C.

) Art Unit: 1647

NOT ENTERED
TECH CENTER 1600/2900

RECEIVED

EEB 2 6 2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Box AF, Washington, D.C. 20231 on January 9, 2002.

Signed: Wendy Wilson
Wendy Wilson

RESPONSE

Commissioner for Patents

Box AF

Washington, D.C. 20231

Sir:

This is in response to the Office Action mailed July 9, 2001 (Paper No. 28). A Notice of Appeal was filed December 10, 2001, together with a Petition for Extension of Time for two months. Please give favorable consideration to the amendments and remarks herein.

IN THE CLAIMS:

Please enter the following amended claim set, cancelling without prejudice, disclaimer or admission all previously pending claims not reiterated herein (i.e., Claims 3, 8 and 9).

Jul 3/02

1. (Four Times Amended) A vascular endothelial cell growth factor (VEGF) antagonist molecule comprising a variant VEGF polypeptide, said variant polypeptide comprising an amino acid modification of at least one cysteine residue at position 51 and/or 60 of the native VEGF, wherein said antagonist molecule is capable of binding to VEGF receptors without significantly inducing a VEGF response, wherein said antagonist molecule is capable of inhibiting a biological activity of a native VEGF protein, wherein said biological activity is induction of a VEGF response.